

119TH CONGRESS
1ST SESSION

H. RES. 685

Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 9, 2025

Mrs. CAMMACK (for herself, Ms. KAMLAGER-DOVE, Mrs. KIM, Ms. PETTERSEN, Mrs. HINSON, Ms. ADAMS, Mrs. CHERFILUS-McCORMICK, and Mr. LANDSMAN) submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

Whereas antiphospholipid syndrome (APS) is a condition in which the immune system of an individual mistakenly produces antibodies that increase the risk of blood clots;

Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy complications;

Whereas professional medical associations and guideline-setting bodies do not recommend testing for APS as a standard part of prenatal screening;

Whereas professional medical associations and guideline-setting bodies recommend testing for APS only if a woman

has an unexplained fetal loss after 10 weeks or 3 or more unexplained embryonic losses (miscarriages);

Whereas APS is responsible for about 15 percent of recurrent pregnancy losses;

Whereas the total number of miscarriages caused by APS is unknown because it is not tested as part of normal prenatal screening;

Whereas APS can be detected by a blood test and treated by blood thinners; and

Whereas testing for APS during normal prenatal screening can save babies and reduce grief for women and families:
Now, therefore, be it

1 *Resolved*, That the House of Representatives—

2 (1) supports testing for antiphospholipid syn-
3 drome (APS) as a standard part of prenatal screen-
4 ing; and

5 (2) calls upon professional medical associations
6 and guideline-setting bodies to update their rec-
7 ommendations to include testing for APS as a
8 standard part of prenatal screening.

○